Self	O
-	O
assembled	O
nanocomplex	B:C1254351
between	O
polymerized	O
phenylboronic	O
acid	I:C0053163
and	O
doxorubicin	O
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	B:C0053163
acid	I:C0053163
and	O
doxorubicin	O
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	O
acid	I:C0053163
and	O
doxorubicin	B:C0013089
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	O
acid	I:C0053163
and	O
doxorubicin	O
for	O
efficient	O
tumor	B:C0027651
-	O
targeted	O
chemotherapy	O
.	O

Self	O
-	O
assembled	O
nanocomplex	O
between	O
polymerized	O
phenylboronic	O
acid	I:C0053163
and	O
doxorubicin	O
for	O
efficient	O
tumor	O
-	O
targeted	O
chemotherapy	B:C3665472
.	O

Since	O
the	O
discovery	O
that	O
nano	O
-	O
scaled	O
particulates	O
can	O
easily	O
be	O
incorporated	O
into	O
tumors	B:C0027651
via	O
the	O
enhanced	O
permeability	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
,	O
such	O
nanostructures	O
have	O
been	O
exploited	O
as	O
therapeutic	O
small	O
molecule	O
delivery	O
systems	I:C0085104
.	O

Since	O
the	O
discovery	O
that	O
nano	O
-	O
scaled	O
particulates	O
can	O
easily	O
be	O
incorporated	O
into	O
tumors	O
via	O
the	O
enhanced	O
permeability	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
,	O
such	O
nanostructures	O
have	O
been	O
exploited	O
as	O
therapeutic	O
small	O
molecule	O
delivery	B:C0085104
systems	I:C0085104
.	O

However	O
,	O
the	O
convoluted	O
synthetic	O
process	O
of	O
conventional	O
nanostructures	O
has	O
impeded	O
their	O
feasibility	B:C0015730
and	O
reproducibility	O
in	O
clinical	O
applications	I:C1880106
.	O

However	O
,	O
the	O
convoluted	O
synthetic	O
process	O
of	O
conventional	O
nanostructures	O
has	O
impeded	O
their	O
feasibility	O
and	O
reproducibility	O
in	O
clinical	B:C1880106
applications	I:C1880106
.	O

Herein	O
,	O
we	O
report	B:C0700287
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	I:C0085104
of	O
the	O
anti-cancer	O
drug	I:C0003392
doxorubicin	O
(	O
doxorubicin	O
)	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	B:C0524527
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	I:C0085104
of	O
the	O
anti-cancer	O
drug	I:C0003392
doxorubicin	O
(	O
doxorubicin	O
)	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	B:C0085104
delivery	I:C0085104
of	O
the	O
anti-cancer	O
drug	I:C0003392
doxorubicin	O
(	O
doxorubicin	O
)	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	I:C0085104
of	O
the	O
anti-cancer	B:C0003392
drug	I:C0003392
doxorubicin	O
(	O
doxorubicin	O
)	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	I:C0085104
of	O
the	O
anti-cancer	O
drug	I:C0003392
doxorubicin	B:C0013089
(	O
doxorubicin	O
)	O
.	O

Herein	O
,	O
we	O
report	O
an	O
easily	O
prepared	O
formulation	O
of	O
self	O
-	O
assembled	O
nanostructures	O
for	O
systemic	O
delivery	I:C0085104
of	O
the	O
anti-cancer	O
drug	I:C0003392
doxorubicin	O
(	O
doxorubicin	B:C0013089
)	O
.	O

Phenylboronic	B:C0053163
acid	I:C0053163
(	O
Phenylboronic	O
acid	I:C0053163
)	O
was	O
grafted	O
onto	O
the	O
polymeric	O
backbone	I:C0032521
of	O
poly	O
(	I:C1254351
maleic	I:C1254351
anhydride	I:C1254351
)	I:C1254351
.	O

Phenylboronic	O
acid	I:C0053163
(	O
Phenylboronic	B:C0053163
acid	I:C0053163
)	O
was	O
grafted	O
onto	O
the	O
polymeric	O
backbone	I:C0032521
of	O
poly	O
(	I:C1254351
maleic	I:C1254351
anhydride	I:C1254351
)	I:C1254351
.	O

Phenylboronic	O
acid	I:C0053163
(	O
Phenylboronic	O
acid	I:C0053163
)	O
was	O
grafted	O
onto	O
the	O
polymeric	B:C0032521
backbone	I:C0032521
of	O
poly	O
(	I:C1254351
maleic	I:C1254351
anhydride	I:C1254351
)	I:C1254351
.	O

Phenylboronic	O
acid	I:C0053163
(	O
Phenylboronic	O
acid	I:C0053163
)	O
was	O
grafted	O
onto	O
the	O
polymeric	O
backbone	I:C0032521
of	O
poly	B:C1254351
(	I:C1254351
maleic	I:C1254351
anhydride	I:C1254351
)	I:C1254351
.	O

pPBA-DOX	B:C1254351
nanocomplexes	I:C1254351
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3	O
-	O
diol	O
of	O
doxorubicin	O
and	O
the	O
PBA	O
moiety	I:C0053163
on	O
pPBA	O
.	O

pPBA-DOX	O
nanocomplexes	I:C1254351
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3	O
-	O
diol	O
of	O
doxorubicin	B:C0013089
and	O
the	O
PBA	O
moiety	I:C0053163
on	O
pPBA	O
.	O

pPBA-DOX	O
nanocomplexes	I:C1254351
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3	O
-	O
diol	O
of	O
doxorubicin	O
and	O
the	O
PBA	B:C0053163
moiety	I:C0053163
on	O
pPBA	O
.	O

pPBA-DOX	O
nanocomplexes	I:C1254351
were	O
prepared	O
by	O
simple	O
mixing	O
,	O
on	O
the	O
basis	O
of	O
the	O
strong	O
interaction	O
between	O
the	O
1,3	O
-	O
diol	O
of	O
doxorubicin	O
and	O
the	O
PBA	O
moiety	I:C0053163
on	O
pPBA	B:C0032521
.	O

Three	O
nanocomplexes	B:C1254351
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
Phenylboronic	O
acid	I:C0053163
]	O
:	O
[	O
doxorubicin	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	I:C0053163
as	O
a	O
targeting	O
ligand	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
Phenylboronic	B:C0053163
acid	I:C0053163
]	O
:	O
[	O
doxorubicin	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	I:C0053163
as	O
a	O
targeting	O
ligand	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
Phenylboronic	O
acid	I:C0053163
]	O
:	O
[	O
doxorubicin	B:C0013089
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	I:C0053163
as	O
a	O
targeting	O
ligand	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
Phenylboronic	O
acid	I:C0053163
]	O
:	O
[	O
doxorubicin	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	B:C0053163
moiety	I:C0053163
as	O
a	O
targeting	O
ligand	O
.	O

Three	O
nanocomplexes	O
(	O
1	O
,	O
2	O
,	O
4	O
)	O
were	O
designed	O
on	O
the	O
basis	O
of	O
[	O
Phenylboronic	O
acid	I:C0053163
]	O
:	O
[	O
doxorubicin	O
]	O
molar	O
ratios	O
of	O
1:1	O
,	O
2:1	O
,	O
and	O
4:1	O
,	O
respectively	O
,	O
to	O
investigate	O
the	O
function	O
of	O
the	O
residual	O
PBA	O
moiety	I:C0053163
as	O
a	O
targeting	O
ligand	B:C1254351
.	O

An	O
acid	O
-	O
labile	O
drug	O
release	O
profile	O
was	O
observed	O
,	O
owing	O
to	O
the	O
intrinsic	O
properties	O
of	O
the	O
phenylboronic	B:C1254351
ester	I:C1254351
.	O

Moreover	O
,	O
the	O
tumor	B:C0027651
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	I:C0242842
and	O
in	O
vivo	I:C1515655
by	O
fluorescence	O
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	B:C1254351
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	I:C0242842
and	O
in	O
vivo	I:C1515655
by	O
fluorescence	O
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	B:C0242842
microscopy	I:C0242842
and	O
in	O
vivo	I:C1515655
by	O
fluorescence	O
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	I:C0242842
and	O
in	B:C1515655
vivo	I:C1515655
by	O
fluorescence	O
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	I:C0242842
and	O
in	O
vivo	I:C1515655
by	O
fluorescence	B:C0430876
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
.	O

Moreover	O
,	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
the	O
nanocomplexes	O
was	O
demonstrated	O
,	O
both	O
in	O
vitro	O
by	O
confocal	O
microscopy	I:C0242842
and	O
in	O
vivo	I:C1515655
by	O
fluorescence	O
imaging	I:C0430876
,	O
to	O
be	O
driven	O
by	O
an	O
inherent	O
property	O
of	O
the	O
residual	O
Phenylboronic	B:C0053163
acid	I:C0053163
.	O

Ligand	B:C0005507
competition	I:C0005507
assays	I:C0005507
with	O
free	O
Phenylboronic	O
acid	I:C0053163
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
from	O
the	O
nanocomplexes	O
2	O
and	O
4	O
.	O

Ligand	O
competition	I:C0005507
assays	I:C0005507
with	O
free	O
Phenylboronic	B:C0053163
acid	I:C0053163
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
from	O
the	O
nanocomplexes	O
2	O
and	O
4	O
.	O

Ligand	O
competition	I:C0005507
assays	I:C0005507
with	O
free	O
Phenylboronic	O
acid	I:C0053163
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
Phenylboronic	B:C0053163
acid	I:C0053163
from	O
the	O
nanocomplexes	O
2	O
and	O
4	O
.	O

Ligand	O
competition	I:C0005507
assays	I:C0005507
with	O
free	O
Phenylboronic	O
acid	I:C0053163
pre-treatment	O
demonstrated	O
the	O
targeting	O
effect	O
of	O
the	O
residual	O
Phenylboronic	O
acid	I:C0053163
from	O
the	O
nanocomplexes	B:C1254351
2	O
and	O
4	O
.	O

Finally	O
,	O
the	O
nanocomplexes	B:C1254351
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	O
DOX	I:C0013089
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	O
effects	O
in	O
vitro	O
and	O
even	O
in	O
vivo	I:C1515655
.	O

Finally	O
,	O
the	O
nanocomplexes	O
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	B:C0013089
DOX	I:C0013089
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	O
effects	O
in	O
vitro	O
and	O
even	O
in	O
vivo	I:C1515655
.	O

Finally	O
,	O
the	O
nanocomplexes	O
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	O
DOX	I:C0013089
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	B:C0003392
effects	O
in	O
vitro	O
and	O
even	O
in	O
vivo	I:C1515655
.	O

Finally	O
,	O
the	O
nanocomplexes	O
2	O
and	O
4	O
,	O
compared	O
with	O
the	O
free	O
DOX	I:C0013089
,	O
exhibited	O
significantly	O
greater	O
anti-cancer	O
effects	O
in	O
vitro	O
and	O
even	O
in	B:C1515655
vivo	I:C1515655
.	O

Our	O
pPBA	B:C1254351
-DOX	I:C1254351
nanocomplex	I:C1254351
enables	O
a	O
new	O
paradigm	O
for	O
self	O
-	O
assembled	O
nanostructures	O
with	O
potential	O
biomedical	O
applications	I:C0752188
.	O

Our	O
pPBA	O
-DOX	I:C1254351
nanocomplex	I:C1254351
enables	O
a	O
new	O
paradigm	O
for	O
self	O
-	O
assembled	O
nanostructures	O
with	O
potential	O
biomedical	B:C0752188
applications	I:C0752188
.	O

